03:27 AM EST, 11/04/2025 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) reported a Q3 adjusted loss late Monday of $0.13 per diluted share, swinging from earnings $0.64 a year earlier.

Analysts surveyed by FactSet expected a loss of $0.32.

Revenue for the quarter ended Sept. 30 was $399.4 million, down from $467.2 million a year earlier.

Analysts polled by FactSet expected $335.8 million.

The company said a phase 3 study evaluating AMONDYS 45 and VYONDYS 53 for the treatment of Duchenne muscular dystrophy did not achieve statistical significance on its primary endpoint. Sarepta plans to meet with the US Food and Drug Administration to discuss the possibility of shifting from accelerated to traditional approval, it said.

Shares of the company were down more than 37% in premarket activity Tuesday.